The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
28280261 |
84 |
Non-kinase targets of protein kinase inhibitors. |
The University of Sydney |
27474927 |
76 |
Synthesis, biological evaluation and molecular modeling studies of imidazo[1,2-a]pyridines derivatives as protein kinase inhibitors. |
Paris-Sud University |
26771245 |
7 |
Recent developments of 2-aminothiazoles in medicinal chemistry. |
Sree Chaitanya College |
26762835 |
342 |
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). |
Icahn School of Medicine At Mount Sinai |
25899335 |
1 |
Synthesis and identification of unprecedented selective inhibitors of CK1e. |
Instituto Universitario De Bio-Org£Nica Antonio Gonz£Lez (Iubo-Ag) |
25191940 |
48 |
Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1d ande with nanomolar inhibitory activity on cancer cell proliferation. |
Ulm University Hospital |
23919824 |
18 |
Ligand-protein interactions of selective casein kinase 1d inhibitors. |
Pfizer |
22749643 |
69 |
Structure-based optimization of oxadiazole-based GSK-3 inhibitors. |
Technische Universit£T Darmstadt |
22944772 |
15 |
Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization. |
TBA |
22726925 |
216 |
Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease. |
Cellzome |
23106386 |
4 |
Structural basis for the potent and selective inhibition of casein kinase 1 epsilon. |
Amgen |
22533818 |
84 |
Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3a. |
Technische Universit£T Darmstadt |
18183025 |
12060 |
A quantitative analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
18077363 |
314 |
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. |
University of Oxford |
22168824 |
4 |
Structural basis for the interaction between casein kinase 1 delta and a potent and selective inhibitor. |
Amgen |
22037378 |
31824 |
Comprehensive analysis of kinase inhibitor selectivity. |
Ambit Biosciences |
21807510 |
31 |
Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas. |
Technische Universit£T Darmstadt |
21375264 |
77 |
Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors |
Roche Palo Alto |
19654408 |
2521 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). |
Ambit Biosciences |
19950901 |
23 |
Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. |
Roche Palo Alto |
19837585 |
46 |
Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). |
National Human Genome Research Institute |
19591487 |
38 |
3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta. |
Eberhard-Karls University |
| 4 |
Benzo[c]quinoliziniums: A new family of inhibitors for protein kinase CK II |
TBA |
16366598 |
51 |
(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. |
Johnson & Johnson Pharmaceutical Research and Development |
15999992 |
25 |
Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors. |
Johnson & Johnson Pharmaceutical Research and Development |
15711537 |
653 |
A small molecule-kinase interaction map for clinical kinase inhibitors. |
Ambit Biosciences |
12941331 |
96 |
Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. |
Johnson & Johnson Pharmaceutical Research & Development |
31757666 |
314 |
Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors. |
Merck |
31647655 |
114 |
Kinase Chemodiversity from the Arctic: The Breitfussins. |
Uit - The Arctic University of Norway |
31400711 |
29 |
Small molecule modulators targeting protein kinase CK1 and CK2. |
China Pharmaceutical University |
30385160 |
10 |
Decreasing the CYP2D6 contribution to metabolism of a CK1? inhibitor. |
Sanofi Us |
30384048 |
365 |
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. |
University of Florida |
30978288 |
113 |
A Selective and Brain Penetrant p38?MAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction. |
Northwestern University |
29630366 |
42 |
Discovery of Inhibitor of Wnt Production 2 (IWP-2) and Related Compounds As Selective ATP-Competitive Inhibitors of Casein Kinase 1 (CK1) ?/?. |
Ulm University Hospital |
29289448 |
127 |
Development of dual casein kinase 1?/1? (CK1?/?) inhibitors for treatment of breast cancer. |
Scripps Florida |
29016121 |
44 |
Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3. |
Novartis Institutes For Biomedical Research |
18251489 |
9 |
Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity. |
Mclean Hospital |
17583335 |
49 |
In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists. |
Abbott Laboratories |
9767635 |
42 |
Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkoxyheteroaryl derivatives. |
University of Bologna |